- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07364630
Efficacy of Human Placental Membrane Products and Standard of Care in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers (BIORESCUE)
A Multicenter, Prospective, Controlled Modified Multi-Platform Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers
The study is a multicenter, prospective, controlled modified multi-platform trial assessing the efficacy of human placental membrane products and standard of care in the management of nonhealing diabetic foot ulcers and venous leg ulcers.
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
This study follows a rescue design: patients in the SOC arm who fail to heal during the BIOCAMP Prospective Modified Dual Platform Multicenter Randomized Controlled Clinical Trial will enter the Rescue trial and receive one of the study products.
Patients enrolled in this trial must still meet medical necessity criteria for cellular, acellular, matrix-like, products (CAMPs) recently published by the Medicare Administrative Contractor's (MAC) in their local coverage determinations (LCD).
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Bennett Sarver
- Numero di telefono: 1-833-865-6300
- Email: info@serenagroups.com
Backup dei contatti dello studio
- Nome: Thomas Serena, MD
- Numero di telefono: 1-833-865-6300
- Email: Info@serenagroups.com
Luoghi di studio
-
-
Pennsylvania
-
Philidelphia, Pennsylvania, Stati Uniti, 19146
- Reclutamento
- Center for Foot and Ankle Disorders
-
Contatto:
- Ryan Breisinger
- Numero di telefono: 412-965-5737
- Email: rbreisinger@serenagroups.com
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- The potential subject must be at least 18 years of age or older.
- The potential subject must have a diagnosis of type 1 or 2 Diabetes mellitus.
- If the potential subject has two or more ulcers, the target ulcer must be the same ulcer treated in the BIOCAMP study.
- The potential subject must consent to using the prescribed offloading method for the duration of the study.
- The potential subject must agree to attend the weekly study visits required by the protocol.
- The potential subject must be willing and able to participate in the informed consent process.
- The potential subject must have participated in the BIOCAMP trial in the SOC only arm and NOT achieved complete closure by the 12-week endpoint.
Exclusion Criteria:
- The potential subject is known to have a life expectancy of < 6 months.
- The potential subject's target ulcer is not secondary to diabetes.
- The target ulcer is infected or there is cellulitis in the surrounding skin.
- The target ulcer exposes tendon or bone.
- There is evidence of osteomyelitis complicating the target ulcer.
- There is an infection in the target ulcer or in a remote location that requires systemic antibiotic therapy.
- The potential subject is receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of prednisone per day or equivalent) or cytotoxic chemotherapy or is taking medications that the PI believes will interfere with wound healing (e.g., biologics).
- The potential subject is taking hydroxyurea.
- The potential subject has applied topical steroids to the ulcer surface within one month of TV-1.
- The potential subject with a previous partial amputation on the affected foot that results in a deformity that impedes proper offloading of the target ulcer.
- The potential subject has glycated hemoglobin (HbA1c) greater than or equal to 12% within 3 months of TV-1.
- The potential subject has an acute Charcot foot, or an inactive Charcot foot, which impedes proper offloading of the target ulcer.
- The potential subject is a woman who is pregnant or considering becoming pregnant within the next 6 months.
- The potential subject has end stage renal disease requiring dialysis.
- The potential subject, in the opinion of the investigator, has a medical or psychological condition that may interfere with study assessments.
- The potential subject has a malnutrition indicator score <17 as measured on the Mini Nutritional Assessment.
- The potential subject did not participate in the BIOCAMP trial.
- The potential subject participated in the BIOCAMP trial and was not randomized to the SOC only arm.
- The potential subject participated in the BIOCAMP trial and achieved complete closure.
- The target ulcer was treated with CAMPs, also defined as skin substitute, or hyperbaric oxygen therapy (HBOT) in the month prior to TV-1.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Altro: Tri-Membrane Wrap™ DFU
Tri-Membrane Wrap™ is an allograft derived from human amniotic membrane. |
Participants will receive weekly applications of Tri-Membrane Wrap™ and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first. |
|
Altro: Membrane Wrap™ DFU
Membrane Wrap™ is an allograft derived from human amniotic membrane. |
Participants will receive weekly applications of Membrane Wrap™ and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first. |
|
Altro: Membrane Wrap-Lite™ DFU
Membrane Wrap-Lite™ is an allograft derived from human amniotic membrane. |
Participants will receive weekly applications of Membrane Wrap-Lite™ and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first. |
|
Altro: Membrane Wrap-Hydro™ DFU
Membrane Wrap-Hydro™ is an allograft derived from human amniotic membrane. |
Participants will receive weekly applications of Membrane Wrap-Hydro™ and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first. |
|
Altro: Tri-Membrane Wrap™ VLU
Tri-Membrane Wrap™ is an allograft derived from human amniotic membrane. |
Participants will receive weekly applications of Tri-Membrane Wrap™ and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first. |
|
Altro: Membrane Wrap™ VLU
Membrane Wrap™ is an allograft derived from human amniotic membrane. |
Participants will receive weekly applications of Membrane Wrap™ and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first. |
|
Altro: Membrane Wrap-Lite™ VLU
Membrane Wrap-Lite™ is an allograft derived from human amniotic membrane. |
Participants will receive weekly applications of Membrane Wrap-Lite™ and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first. |
|
Altro: Membrane Wrap-Hydro™ VLU
Membrane Wrap-Hydro™ is an allograft derived from human amniotic membrane. |
Participants will receive weekly applications of Membrane Wrap-Hydro™ and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Percentage of Wound Closure
Lasso di tempo: 1-12 Weeks
|
The percentage of target ulcers achieving complete wound closure in 12 weeks. |
1-12 Weeks
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Time to Closure
Lasso di tempo: 1-12 weeks
|
Time to closure for the target ulcer. |
1-12 weeks
|
|
Percentage Area Reduction
Lasso di tempo: 1-12 weeks
|
Percentage wound area reduction from TV-1 to TV-13 measured weekly with digital photographic planimetry, using imaging device, and physical examination. |
1-12 weeks
|
|
Adverse Events
Lasso di tempo: 1-12 Weeks
|
The number of product- or procedure- related adverse events. |
1-12 Weeks
|
|
Determine improvement in Quality of Life
Lasso di tempo: 1-12 weeks
|
To determine the between-arm difference in the quality of life for subjects receiving HPM plus SOC compared to SOC alone using the Forgotten Wound Score (FWS) questionnaire. Forgotten wound scores situations on a scale of "never" to "mostly." |
1-12 weeks
|
|
Determine improvement in Quality of Life
Lasso di tempo: 1-12 weeks
|
To determine the between-arm difference in the quality of life for subjects receiving HPM plus SOC compared to SOC alone using the Wound Quality of Life (wQOL) questionnaire. Scores on a scare from "Not at all" to "Very much." |
1-12 weeks
|
|
Pain in patients who present with VAS greater than 4
Lasso di tempo: 1-12 Weeks
|
To determine the between-arm difference in pain for patients that present with a Visual Analog Sale (VAS) score of greater than 4. The VAS has a scale of 0-10. 0 Meaning no pain and 10 being the worst pain |
1-12 Weeks
|
Collaboratori e investigatori
Sponsor
Collaboratori
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie del sistema endocrino
- Malattie vascolari
- Malattia cardiovascolare
- Processi patologici
- Diabete mellito
- Angiopatie diabetiche
- Complicanze del diabete
- Malattie della pelle
- Ulcera della pelle
- Vene varicose
- Neuropatie diabetiche
- Malattie del piede
- Condizioni patologiche, segni e sintomi
- Malattie della pelle e del tessuto connettivo
- Ulcera
- Ulcera varicosa
- Ulcera alla gamba
- Piede diabetico
- Ulcera del piede
Altri numeri di identificazione dello studio
- RescueX
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .